The investment is designed to advance and accelerate the company's development of CTAP101 Capsules, a product currently in a Phase 2b study for the treatment of secondary hyperparathyroidism associated with vitamin D insufficiency in patients with non-dialysis chronic kidney disease.
The product is designed to reliably raise serum total vitamin D pro-hormone concentrations to levels of 30 ng/mL or higher, while also lowering the risk of side effects associated with other vitamin D treatments, according to Cytochroma.
"Cytochroma demonstrates great potential to develop and commercialize new treatments to global health problems and create new jobs for Ontario families," said Michael Chan, Member of Provincial Parliament, Markham-Unionville. "We're proud to help tomorrow's industry leaders get their start today here in Markham."
Funded by the Government of Ontario, the fund is a $7 million program that helps innovative life sciences companies turn their discoveries into new products and services that meet patient needs.
